Literature DB >> 17309185

99mTc-MIBI myocardial perfusion scintigraphy for assessment of myocardial damage after radiotherapy in patients with breast cancer.

A Tzonevska1, K Tzvetkov, V Parvanova, M Dimitrova.   

Abstract

PURPOSE: After radiation therapy (RT) to the thorax, cardiac injuries may be induced involving the myocardial capillaries and causing myocardial fibrosis. The aim of this study was to assess the role of 99mTc-MIBI myocardial perfusion scintigraphy (MPS) for mapping the RT-induced cardiac injuries. PATIENTS AND METHODS: The study involved 56 patients: 46 with left-sided(study group) and 10 with right-sided (control group) breast cancer who, after breast surgery, received postoperative RT. In the cases of the study group, the anterior wall of the myocardium was included in the target field. All of the patients were asymptomatic and without risk factors concerning heart. 99m Tc-MIBI MPS was performed using Siemens Diacam gamma camera. 555 MBq of tracer was injected in each occasion. MPS was performed 30-60 min after injection and the images were analyzed using a semi quantitative four-point system.
RESULTS: MPS was normal in all patients of the control group and in 33 (76%) patients of the study group. In 11 (24%) of the patients in the study group MPS indicated moderately reduced perfusion: 7 of the patients had hypo-perfusion of the anterior wall segments, 4 had hypoperfused septum and apex. Comparison of the 2 groups showed statistically significant difference (p<0.001).
CONCLUSION: Cardiac injury after irradiation of the thorax is not rare and its early detection may minimize severe cardiac damage. MPS may be a feasible method to that purpose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17309185

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

Review 2.  The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology.

Authors:  Matthew K Burrage; Vanessa M Ferreira
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

3.  Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy.

Authors:  Hana Kalábová; Bohuslav Melichar; Leoš Ungermann; Jiří Doležal; Lenka Krčmová; Markéta Kašparová; Jiří Plíšek; Radomír Hyšpler; Miroslav Pecka; Dagmar Solichová
Journal:  Med Oncol       Date:  2010-06-22       Impact factor: 3.064

4.  15O-H2O PET/CT as a tool for the quantitative assessment of early post-radiotherapy changes of heart perfusion in breast carcinoma patients.

Authors:  Agnieszka Żyromska; Bogdan Małkowski; Tomasz Wiśniewski; Karolina Majewska; Joanna Reszke; Roman Makarewicz
Journal:  Br J Radiol       Date:  2018-07-20       Impact factor: 3.039

5.  Myocardial perfusion years after radiation therapy for left-sided breast cancer: Normal or abnormal? This is the question.

Authors:  Alberto Aimo; Alessia Gimelli
Journal:  J Nucl Cardiol       Date:  2019-11-19       Impact factor: 5.952

6.  Myocardial perfusion imaging with (99 m)Tc-tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study.

Authors:  Chrissa Sioka; Thomas Exarchopoulos; Ifigenia Tasiou; Eftychia Tzima; Nikolaos Fotou; Antonio Capizzello; Vasilios Ragos; Periklis Tsekeris; Andreas Fotopoulos
Journal:  Radiat Oncol       Date:  2011-11-08       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.